Value Investor
Start free

Inventiva

IVA on Nasdaq. Pharmaceutical preparations. Market value $841m.

Watch this stockFree. We tell you when something changes.

This company reports once a year (it is based outside the US), so every figure comes from its annual report for the year to December 2024.

We can't read total debt from the filing, so debt is left out.

Cash flow or capital spending isn't reported, so free cash flow is unknown.

We can't pin down how many shares it has, so we don't rank it.

The latest annual report is over 15 months old, so we don't rank it.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

Nothing stands out yet.

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2024
n/a

We could not compute this from the filings.

Price to profit
annual report to December 2024
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2024
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: not known. Our list needs 70 on quality and 60 on price.

$3.46 a share, 11% above its 1-year low

Over the past year the price has ranged from $3.11 to $7.98.

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

n/a
n/a
n/a
n/a
n/a
20202021202220232024
Revenue
n/an/an/an/an/a
Operating margin
n/an/an/an/an/a
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.04bn0.04bn0.04bn0.05bn0.10bn

Health checks

  • Free cash flow positiveNot enough data
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Not enough data
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 148% more shares since 2020

Dates

Next results (estimated)
n/a
Last annual report (10-K)
8 April 2026
Next quarterly (estimated, 10-Q)
n/a

Who owns it

None of the long-term investors we follow own it. 88 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

11 investors own more than 5%.

  • Invus Public Equities, L.P.
    Passive investor
    at least 10.6%+2.8 pts
    (filed with 4 related holders)
    Since 30 June 2025
  • Sofinnova Partners SAS, a French corporation
    Passive investor
    at least 8.6%+1.4 pts
    (filed with 7 related holders)
    Since 31 December 2025
  • Andera Partners
    Passive investor
    at least 7.7%−1.1 pts
    (filed with 3 related holders)
    Since 31 December 2025
  • Srinivas Akkaraju
    at least 7.4%+1.5 pts
    (filed with 4 related holders)
    Since 17 November 2025
  • at least 5.5%
    (filed with 3 related holders)
    Since 30 September 2025
  • at least 5.0%−1.1 pts
    (filed with 9 related holders)
    Since 17 November 2025
  • Perceptive Advisors LLC
    Passive investor
    at least 5.0%−0.8 pts
    (filed with 2 related holders)
    Since 30 September 2025
  • New Enterprise Associates 17, L.P.
    Passive investor
    at least 4.9%−1.1 pts
    (filed with 15 related holders)
    Since 30 March 2026
    What they said

    NEA 17 acquired the NEA 17 Shares for investment purposes and GEO acquired the GEO Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17, GEO and other Reporting Persons may…

    Read the filing
  • at least 4.6%−2.1 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • Deep Track Capital, LP
    Passive investor
    at least 3.8%−2.3 pts
    (filed with 2 related holders)
    Since 31 March 2026
  • at least 3.5%−2.6 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • Pierre Broqua
    Passive investor
    Sold down below 5%
    Since 31 December 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

We have no insider filings for this company yet.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

Inventiva doesn’t file a US annual report (10-K), so we haven’t checked it.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.